W Timothy Garvey, ADA 2022: Semaglutide for type 2 diabetes, the 10-year risk in patients with obesity

A risk stratification tool has been developed that enables the prediction of the 10-year risk of patients with obesity developing type 2 diabetes. Dr W Timothy Garvey (University of Alabama at Birmingham, Birmingham, AL, USA) discusses the tool, named Cardiometabolic Disease Scoring, the impact of semaglutide on the risk of developing type 2 diabetes and the implications for prevention. 

The abstract entitled ‘Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity‘ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.

Questions: 

1. How did you assess the 10-year risk of type 2 diabetes using data from the STEP program? (0:26)
2. What impact did semaglutide have on the 10-year risk of developing diabetes, including the effect of baseline glycaemic status on results? (2:31)
3. In your opinion, what are the implications of this study’s results for preventing type 2 diabetes in overweight and obese people? (4:00)

Disclosures: W Timothy Garvey is on the advisory board for Alnam, Boehringer-Ingelheim, Eli Lilly, Fractyl, JAZZ Pharmaceuticals, Novo Nordisk and Pfizer. W Timothy Garvey has received grant/research support from Eli Lilly, Epitomee, Novo Nordisk and Pfizer. All clinical trials were sponsored by the University of Alabama at Birmingham.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ADA 2022.